Skp2在鼻型NK/T细胞淋巴瘤中的表达及临床意义

The expression and clinical significance of Skp2 in nasal type NK/T-cell lymphoma

目的探讨Skp2与鼻型NK/T细胞淋巴瘤的预后及其他临床特点之间的关系。方法收集95例鼻型NK/T细胞淋巴瘤患者临床病理学资料,用免疫组化方法检测肿瘤石蜡包埋标本的EB病毒编码RNA(EBV encoded RNA,EBER)、Skp2及Ki-67的表达情况,将Skp2阳性细胞比率超过50%的病例计入高表达组,低于50%的计入低表达组,分析患者的预后、EBER表达状态与Skp2、Ki-67表达率之间的关系。结果在Skp2高表达组,中位生存期为20.54个月(95%CI:18.49-22.59),1年总体生存率为76%;在Skp2低表达组,中位生存期为17.54个月(95%CI:20.31-22.24),1年总体生存率为71%;在Skp2阴性组,中位生存期为个21.71个月(95%CI:11.15-16.18),1年总体生存率为91%。生存分析显示,Skp2高表达组与Skp2阴性组间差异具有统计学意义(P=0.035)。结论 Skp2的高表达可能是鼻腔NK/T细胞淋巴瘤预后的不良因素。

Objective To discuss the correlation between Skp2 and the prognosis and other clinicopathological features of nasal type NK/T-cell lymphoma. Methods We collected the clinicopathological data of 95 cases of nasal type NK/T-cell lymphoma,detected the expression of EBV encoded RNA （EBER）, Skp2 and Ki-67 of paraffin-embedded tissue of tumors using immunohistochemical method. The cases with the Skp2-positive rate of tumor cells above 50% were classified into high expression group, those with below 50 % were classified into low expression group. We analyzed the correlation between the expression of Skp2 and Ki-67, and the prognosis or EBER status. Results In the high expression group,the mean overall survival was 20.54 months （95%CI. 18.49 - 22.59）, the 1-year overall survival rate was 76%. In the low expression group, the mean overall survival was 17.54 months （95%CI.20.31 - 22.24） ,the 1-year overall survival rate was 71%.In the negative expression group, the mean overall survival was 21. 71 months （95% CI.-11. 15 - 16.18） ,the 1-year overall survival rate was 91%. There was statistical difference between Skp2 high expression group and Skp2 negative expression group （P（0.01）. Conclusions The high expression of Skp2 maybe an independent unfavorable prognosis factor of nasal type NK/T-cell lymphoma.